Theragnostics

prnewswire.com/news-releases/….

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport. #GBM #Cancer #cancerawareness #radiopharmaceuticals #glioblastoma

@Theragnostics today announces licensing agreement for development and commercialization of one-step PET radiopharmaceuticals. prnewswire.co.uk/news-releases/… #biotech #oncology #radiopharmaceuticals #cancer #developement #commercialisation @Novartis @Advancedacceleratorapplications

@Theragnostics is delighted to announce the appointments of key drug development experts Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to our Board as we prepare for the next stage of growth. Read more: theragnostics.com/theragnostics-… #biotech #oncology #cancer

Today we are delighted to announce our research collaboration with Essen University Hospital theragnostics.com/theragnostics-… #theragnostics #cancer #parpi

Theragnostics is excited to share how we are utilizing PARP inhibitors to target cancer cells and progress the field cancer research!

Great to see increasing interest in the next generation of radiopharmaceuticals” with a link to this article? RayzeBio debuts with $45M to target tumors with radiopharmaceuticals: fiercebiotech.com/biotech/rayzeb…

We are proud to support #OvarianCancerAwarenessMonth as we continue to work on the development of our targeted #radionuclide THG-009. Spotting signs and symptoms earlier is crucial. @OvarianCancerUK explains what you should be looking out for: bit.ly/2HnMPbC

Pleased to announce our deal with Summit Biomedical Imaging LLC #theragnostics #cancer #parpi prweb.com/releases/summi…

Theragnostics is proud to announce our collaboration with the ‘Next generation molecular imaging and therapy with radionuclide’ (MITHRAS) programme currently launching in the UK. theragnostics.com/theragnostics-…

The Theragnostics team are on lock down but still supporting Brain Tumour Research today with #WearAHatDay. Please donate here: lnkd.in/d3NjMXN #braintumour #braincancer #cancerresearch (Thanks to Daniel Tiller for helping with the collage!) @braintumourrsch

@Theragnostics CEO Greg Mullen will be attending the Prostate Cancer PSMA Masterclass this week at @ExploreWelcome in partnership with @UCL. More information: bit.ly/2PD7t8X Register here: bit.ly/38hVpjR #radiopharmaceuticals #oncology #WellcomeTrust #PSMA

Theragnostics has an exciting new position to fill in our US office: lnkd.in/dKJudiT

@Theragnostics management team have arrived in San Francisco to attend #JPM2020. CEO Greg Mullen and COO Gareth Smith will be attending and hosting meetings at JPM in SF. Reach out to us!#PARPi #radiopharmaceuticals #oncology #biotech theragnostics.com/theragnostics-…

CEO Greg Mullen will be speaking on the panel “Meeting Biotech Rising Stars” at #Genesis Conference

We are working hard to develop and perfect our single step cold kit Prostate Cancer Diagnostic, #PSMA. We strive to reach more people by making Prostate Diagnostic Imaging more accessible . See how at theragnostics.com/galli/

Theragnostics would like to say thanks to our Director of Project Management and Business Development, Aaron Block, for showing his support for #prostatecancerawarenessmonth with an impressive mustache. #Movember

#Theragnostics strengthens leadership team with two key appointments: Chris Sterling appointed as Non-Executive Director. #Radiopharmaceutical #drugdevelopment expert Dr Daniel Stevens joins as Chief Medical Officer prnewswire.com/news-releases/…

18F-PARPi Phase I trial data in head & neck cancer goes into the public domain. Just the beginning for rPARPi. #Theragnostics #rPARPi #Clinicaltrials medrxiv.org/content/10.110…

Fantastic news from our friends at @Theragnostics who have partnered with @GEHealthcare for late stage PSMA diagnostic for #ProstateCancer There novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. Great collab.